Fibroscan, Liver Elastography, and Non-Invasive Liver Assessments

fibroscangraphic

Liver fibrosis and cirrhosis are the result of chronic liver injury from a range of causes. Careful evaluation of the clinical history, laboratory values, imaging studies, and sometimes liver biopsy remains essential. In most cases, specialists have replaced liver biopsy, the traditional gold standard for assessing liver health, with non-invasive methods:

  • Estimating liver stiffness or tissue elasticity by measuring shear wave propagation speed (cs)
  • Applying blood enzyme and protein levels into fibrosis scores

Liver Biopsy: Strengths and Limitations

Liver biopsy remains the imperfect but important gold standard for diagnosing liver disease and staging fibrosis. Its strength lies in its long-established history and the diversity of findings in one test. Without it, things are not always as they seem. It provides essential information where:

  • The cause of liver abnormalities is unclear. For example, a patient with diabetes, obesity, and abnormal liver enzymes may have autoimmune hepatitis (AIH) or an overlap of AIH and steatohepatitis. A treated AIH patient with persistent enzyme elevation may have inadequately treated AIH or may have developed metabolic dysfunction-associated fatty liver disease (MAFLD) after steroid-induced weight gain.
  • Unexpected findings such as granulomatous inflammation, bile duct injury, or venous congestion are possible.
  • Measurement of tissue metal content (e.g., hemochromatosis, Wilson’s disease) is required.

However, biopsy is invasive and carries non-trivial risks, including:

  • Pain, hypotension
  • Haemorrhage
  • Injury to adjacent organs (gallbladder, colon, pleura, kidney, pancreas)
  • Sampling error: liver biopsies sample only about 1/50,000 of the total liver volume. Even high-quality percutaneous biopsies (~25 mm) misclassify fibrosis stage approximately 25% of the time compared to larger surgical specimens.

Liver Stiffness Measurement (LSM) with Elastography

The stiffness of your liver can be measured non-invasively with elastography. This is most commonly done at the time of a routine liver ultrasound using shear wave elastography (SWE). In specialist practice, transient elastography (TE) or magnetic resonance elastography (MRE) may be used.

Fibroscan® (Echosens, Paris) uses vibration-controlled transient elastography (VCTE). It was the first commercially available elastography method and remains the technique with the most advanced quality criteria, validation, and evidence base. It is a 10-minute, non-invasive, painless procedure experienced much like a liver ultrasound. A 5 MHz ultrasound transducer probe, mounted on the axis of a vibrator, transmits mild-amplitude, low-frequency vibrations (50 Hz) into the liver tissue, inducing an elastic shear wave that propagates through the underlying tissue. Patients describe the sensation as unusual but not painful — like a gentle flick or tap against the side. The velocity of the wave is directly related to tissue stiffness. The technique measures stiffness in a cylindrical volume approximately 1 cm in diameter and 4 cm in length, amounting to about 1/500 of the entire liver volume — 100 times larger than the volume sampled by a typical liver biopsy.

Shear Wave Elastography (SWE) is the most commonly used method in general radiology practices. SWE is performed as part of a standard ultrasound examination, using acoustic pulses from the ultrasound probe to generate internal shear waves within the liver. Like Fibroscan, SWE measures how fast these waves travel through the liver to estimate stiffness. Patients usually do not feel any sensation during SWE. Although the measurement method differs slightly, SWE provides a reliable and non-invasive way to assess liver health in routine clinical practice. Most radiology practices report liver stiffness using Shear Wave Elastography (SWE), often incorrectly using the brand "Fibroscan". SWE results can vary slightly between machines and software versions, due to differences in calibration and algorithms. Much like bone densitometry (DEXA), it is often impractical to ensure the same machine or software is used over years of follow-up. Fibroscan (TE) remains the most validated and standardised method for liver stiffness assessment. However, SWE shows comparable accuracy at the extremes — particularly when liver stiffness is <7.5 kPa or >9.0 kPa.

Magnetic Resonance Elastography (MRE) uses external vibrations, like TE, to generate mechanical waves through the liver. Specialised MRI sequences then image the propagation of these waves to create a detailed liver stiffness map. It is rarely ordered but MRE provides highly accurate assessment across the whole liver and is particularly useful when ultrasound-based elastography is limited, such as in large or multiple liver cysts/lesions, obesity or ascites.

fibroscanphysics
Fibroscan report sample

Important Differences Between SWE and Fibroscan (TE)

Feature Shear Wave Elastography (SWE) Fibroscan (Transient Elastography, TE)
How shear wave is generated Acoustic radiation force (ultrasound pulse) Mechanical external pulse
Equipment Standard ultrasound machine Dedicated Fibroscan® device
Availability Widely available Specialist settings
Calibration Machine-specific (some variability) Highly standardised globally
Interpretation thresholds Slightly higher readings than TE at low fibrosis stages Standard fibrosis thresholds validated for TE

 

General Interpretation of SWE and Fibroscan (TE) Readings

SWE (kPa) TE (kPa) Interpretation (likely) Suggested Action
<7.5 <7.0 No significant fibrosis Routine monitoring
7.5–8.0 7.0–8.0 Borderline; mild fibrosis Consider clinical context
>8.0–9.5 >8.0–9.5 Suspicious for fibrosis Recommend confirmation with Fibroscan (TE)
>9.5–12.0 >9.5–12.5 Significant fibrosis Fibroscan (TE) or specialist review recommended
>12.0 >12.5 Advanced fibrosis or cirrhosis Specialist referral strongly recommended

 

Further review may be appropriate when:

  • Rising SWE readings over time, even if liver enzymes remain stable.

  • SWE >7.5 kPa in a patient with:

    • Metabolic risk factors (eg, BMI >30, diabetes, dyslipidaemia).

    • History of alcohol use (>14 standard drinks/week for men; >7 for women).

    • New, persistent, or unexplained elevated liver enzymes:

      • ALT or AST >2 × ULN (Upper Limit of Normal; ULN) where AST 30 U/L (female), 20 U/L (male)).

      • GGT >2 × ULN.

Practical guidance:

The below colour charts refer to Fibroscan (TE) not ultrasound Shearwave (SWE). If SWE >8.0 kPa and management decisions depend on accurate fibrosis staging, confirm with Fibroscan (TE) where available. When reading SWE reports: Confirm IQR/Median <30%, success rate >60%, and good technical quality comment.

 

lsmbycastera
fibroscanscorecard

Liver Scores and Biomarkers

Blood-based scores improve fibrosis assessment, especially when combined with elastography:

  • APRI (AST to Platelet Ratio Index)
  • FIB-4 (Age, AST, ALT, platelets)
  • ELF (Enhanced Liver Fibrosis Score: TIMP-1, PIIINP, HA)
  • FibroTest (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT)

Liver Fat (CAP) Score

Fat accumulation (steatosis) is assessed non-invasively using Fibroscan's Controlled Attenuation Parameter (CAP):

  • Measured in decibels per meter (dB/m)
  • Scores range from 100 to 400 dB/m
  • Higher CAP scores reflect greater degrees of steatosis
CAP score

Methotrexate (MTX) and Liver Stiffness Monitoring

Methotrexate (MTX) is widely used in inflammatory diseases. Long-term use can lead to hepatic fibrosis, particularly in the presence of additional risk factors such as obesity, diabetes, alcohol use, or pre-existing liver disease. The overall risk of serious liver injury is low.

In modern practice, liver stiffness monitoring with non-invasive methods such as SWE or TE has replaced routine liver biopsy for surveillance. Fibroscan (TE) remains the most validated and standardised method, but SWE provides useful information, particularly when liver stiffness is <7.5 kPa or >9.0 kPa.

Practical Clinical Note

Long-term MTX monitoring:

  • LFTs every 3–6 months once stable.
  • Baseline viral hepatitis screening and metabolic risk screening
  • Elastography every 5 years if cumulative MTX dose > 5 grams and ongoing MTX plan ( SWE ok ;TE if >8 kPA)
    • Earlier if red flags appear eg. abnormal LFTs, weight gain, new diabetes, or heavy alcohol use
  • Perform an extended liver screen if persistent LFT elevation (>2× ULN) or clinical concern arises.

Routine vs Expanded Liver Screening During Methotrexate Therapy

Scenario Tests Recommended
Routine Monitoring (stable patient, normal LFTs)
  • LFT
  • FBC & eGFR
  • HBsAg, anti-HBc, anti-HCV
  • HbA1c, fasting BSL/lipids/HDL (screening for metabolic syndrome)
Expanded Testing (persistent abnormal LFTs, or clinical suspicion)
  • Repeat LFT and Fibroscan (TE)
  • Ferritin and transferrin saturation (iron studies)
  • HFE genotype testing (only if transferrin saturation >45%)
  • Serum copper and ceruloplasmin (Wilson’s disease screening)
  • Alpha-1 antitrypsin level
  • ANA, ASMA, AMA, ALKMA, Igs +/-EPG/IEPG (autoimmune liver disease screen)

Summary

  • If LFTs are normal and Fibroscan <7.0 kPa → continue routine monitoring (LFTs 3–6 monthly; Fibroscan every 5 years).
  • If LFTs are >2× ULN or Fibroscan ≥8.0–9.5 kPa → consider expanded testing and/or hepatology referral.
  • Obesity (BMI >30), diabetes, heavy alcohol use (>14/week for men, >7/week for women), or new hepatomegaly on examination/imaging are clinical triggers to lower the threshold for Fibroscan or broader testing.

 

diagnostic algorithm for interpreting transient
elastography measurement results in liver disease